[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100374056":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":28,"centralContacts":33,"locations":39,"responsibleParty":220,"collaborators":21,"id":222,"slug":223,"hasResults":224,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":21,"eligibilityCriteria":228,"healthyVolunteers":224,"sex":229,"minAge":230,"maxAge":231,"enrollmentInfo":232,"targetDuration":21,"studyType":235,"phases":236,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":42,"whyStopped":21,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":257},{"fullName":5,"class":6},"Cellectis S.A.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation","EXPERIMENTAL","Several tested doses of UCART22 until the Maximum Tolerated Dose (MTD) is identified and establish Recommended Phase 2 Dose (RP2D)\n\nDose Expansion: UCART22 administered at the RP2D",[13,14],"Biological: UCART22","Biological: CLLS52",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"BIOLOGICAL","UCART22","Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"CLLS52","A monoclonal antibody that recognizes a CD52 antigen",[9],[27],"Alemtuzumab",[29],{"name":30,"affiliation":31,"role":32},"Nitin Jain, MD","M.D. Anderson Cancer Center","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":21,"email":38},"Cellectis Central Contact","CONTACT","+1 (347) 752-4044","clinicaltrials@cellectis.com",[40,54,64,73,83,93,103,111,118,128,138,148,157,166,176,187,196,202,211],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":21},"University of California, Los Angeles (UCLA) - Medical Center","RECRUITING","Los Angeles","California","90095","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-118.24368,34.05223,{"lat":52,"lon":51},{"facility":55,"status":42,"city":56,"state":57,"zip":58,"country":46,"countryCode":47,"cosmosGeoPoint":59,"geoPoint":63,"contacts":21},"University of Colorado - Aurora Cancer Center","Aurora","Colorado","80045",{"type":49,"coordinates":60},[61,62],-104.83192,39.72943,{"lat":62,"lon":61},{"facility":65,"status":42,"city":66,"state":57,"zip":67,"country":46,"countryCode":47,"cosmosGeoPoint":68,"geoPoint":72,"contacts":21},"Sarah Cannon - Colorado Blood Cancer Institute","Denver","80218",{"type":49,"coordinates":69},[70,71],-104.9847,39.73915,{"lat":71,"lon":70},{"facility":74,"status":42,"city":75,"state":76,"zip":77,"country":46,"countryCode":47,"cosmosGeoPoint":78,"geoPoint":82,"contacts":21},"University of Chicago","Chicago","Illinois","60647",{"type":49,"coordinates":79},[80,81],-87.65005,41.85003,{"lat":81,"lon":80},{"facility":84,"status":42,"city":85,"state":86,"zip":87,"country":46,"countryCode":47,"cosmosGeoPoint":88,"geoPoint":92,"contacts":21},"Dana Farber Cancer Institute","Boston","Massachusetts","02215",{"type":49,"coordinates":89},[90,91],-71.05977,42.35843,{"lat":91,"lon":90},{"facility":94,"status":42,"city":95,"state":96,"zip":97,"country":46,"countryCode":47,"cosmosGeoPoint":98,"geoPoint":102,"contacts":21},"Roswell Park Comprehensive Cancer Center","Buffalo","New York","14263",{"type":49,"coordinates":99},[100,101],-78.87837,42.88645,{"lat":101,"lon":100},{"facility":104,"status":42,"city":96,"state":96,"zip":105,"country":46,"countryCode":47,"cosmosGeoPoint":106,"geoPoint":110,"contacts":21},"Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center","10021",{"type":49,"coordinates":107},[108,109],-74.00597,40.71427,{"lat":109,"lon":108},{"facility":112,"status":113,"city":96,"state":96,"zip":114,"country":46,"countryCode":47,"cosmosGeoPoint":115,"geoPoint":117,"contacts":21},"Weill Medical College of Cornell University","WITHDRAWN","10065",{"type":49,"coordinates":116},[108,109],{"lat":109,"lon":108},{"facility":119,"status":42,"city":120,"state":121,"zip":122,"country":46,"countryCode":47,"cosmosGeoPoint":123,"geoPoint":127,"contacts":21},"Children's Hospital of Philadelphia","Philadelphia","Pennsylvania","19104",{"type":49,"coordinates":124},[125,126],-75.16362,39.95238,{"lat":126,"lon":125},{"facility":129,"status":42,"city":130,"state":131,"zip":132,"country":46,"countryCode":47,"cosmosGeoPoint":133,"geoPoint":137,"contacts":21},"Sarah Cannon - HCA Research Institute","Nashville","Tennessee","37203",{"type":49,"coordinates":134},[135,136],-86.78444,36.16589,{"lat":136,"lon":135},{"facility":139,"status":42,"city":140,"state":141,"zip":142,"country":46,"countryCode":47,"cosmosGeoPoint":143,"geoPoint":147,"contacts":21},"Sarah Cannon - St. David's South Austin Medical Center","Austin","Texas","78704",{"type":49,"coordinates":144},[145,146],-97.74306,30.26715,{"lat":146,"lon":145},{"facility":149,"status":42,"city":150,"state":141,"zip":151,"country":46,"countryCode":47,"cosmosGeoPoint":152,"geoPoint":156,"contacts":21},"MD Anderson Cancer Center","Houston","77030",{"type":49,"coordinates":153},[154,155],-95.36327,29.76328,{"lat":155,"lon":154},{"facility":158,"status":42,"city":159,"state":141,"zip":160,"country":46,"countryCode":47,"cosmosGeoPoint":161,"geoPoint":165,"contacts":21},"Sarah Cannon - Texas Transplant Institute at Methodist Hospital","San Antonio","78229",{"type":49,"coordinates":162},[163,164],-98.49363,29.42412,{"lat":164,"lon":163},{"facility":167,"status":42,"city":168,"state":169,"zip":170,"country":46,"countryCode":47,"cosmosGeoPoint":171,"geoPoint":175,"contacts":21},"University of Wisconsin Carbone Cancer Center","Madison","Wisconsin","53792",{"type":49,"coordinates":172},[173,174],-89.40123,43.07305,{"lat":174,"lon":173},{"facility":177,"status":42,"city":178,"state":21,"zip":179,"country":180,"countryCode":181,"cosmosGeoPoint":182,"geoPoint":186,"contacts":21},"CHU de Nantes - Hôtel-Dieu","Nantes","44093","France","FR",{"type":49,"coordinates":183},[184,185],-1.55336,47.21725,{"lat":185,"lon":184},{"facility":188,"status":42,"city":189,"state":21,"zip":190,"country":180,"countryCode":181,"cosmosGeoPoint":191,"geoPoint":195,"contacts":21},"Hôpital Saint Louis, Unité d'Hématologie Adolescents et Jeunes Adultes Département d'Hématologie","Paris","75010",{"type":49,"coordinates":192},[193,194],2.3488,48.85341,{"lat":194,"lon":193},{"facility":197,"status":42,"city":189,"state":21,"zip":198,"country":180,"countryCode":181,"cosmosGeoPoint":199,"geoPoint":201,"contacts":21},"Hôpital Robert Debré - Service d'hémato-immunologie","75019",{"type":49,"coordinates":200},[193,194],{"lat":194,"lon":193},{"facility":203,"status":42,"city":204,"state":21,"zip":205,"country":180,"countryCode":181,"cosmosGeoPoint":206,"geoPoint":210,"contacts":21},"Hôpital Lyon Sud","Pierre-Bénite","69310",{"type":49,"coordinates":207},[208,209],4.82424,45.70359,{"lat":209,"lon":208},{"facility":212,"status":42,"city":213,"state":21,"zip":214,"country":180,"countryCode":181,"cosmosGeoPoint":215,"geoPoint":219,"contacts":21},"CHU Rennes - Hopital Pontchaillou","Rennes","35033",{"type":49,"coordinates":216},[217,218],-1.67431,48.11109,{"lat":218,"lon":217},{"type":221,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100374056","phase-1-phase-12-study-of-ucart22-in-patients-with-relapsed-or-refractory-cd22-b-cell-acute-lymphoblastic-leukemia-balli-01-100374056",false,"NCT04150497","Phase 1\u002F2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)","Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)","Inclusion Criteria:\n\n* B-ALL blast cells expressing CD22\n* Diagnosed with R\u002FR B-ALL\n* Prior therapy must include at least one standard chemotherapy regimen and at least one salvage regimen\n\nExclusion Criteria:\n\n-Prior cellular therapy or investigational cellular or gene therapy within 90 days prior to enrollment","ALL","15 Years","50 Years",{"count":233,"type":234},52,"ESTIMATED","INTERVENTIONAL",[237,238],"PHASE1","PHASE2","This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)",[241],"B-cell Acute Lymphoblastic Leukemia",[243,244,245,246,247],"B-cell Acute Lymphoblastic Leukemia (B-ALL)","Relapse\u002FRefractory B-ALL","Universal Chimeric Antigen Receptor T-Cell (UCAR-T) Therapy","Allogeneic","Transcription Activator-Like Effector Nuclease (TALEN®)","2025-09-08",{"date":250,"type":251},"2025-09-09","ACTUAL",{"date":253,"type":251},"2019-10-14",{"date":255,"type":234},"2026-06-30",{"name":5,"class":6},19]